State of the art: medical treatment of Peyronie's disease
EXPERT OPINION ON ORPHAN DRUGS, vol.1, no.11, pp.867-876, 2013 (SCI-Expanded)
- Publication Type: Article / Review
- Volume: 1 Issue: 11
- Publication Date: 2013
- Doi Number: 10.1517/21678707.2013.851026
- Journal Name: EXPERT OPINION ON ORPHAN DRUGS
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.867-876
- Keywords: erectile dysfunction, oral therapies, Peyronie's disease, sexual dysfunction, COLLAGENASE CLOSTRIDIUM-HISTOLYTICUM, PROPIONYL-L-CARNITINE, INTRALESIONAL INTERFERON-ALPHA-2B, DOUBLE-BLIND, TUNICA ALBUGINEA, LOCAL INTERFERON-ALPHA-2B, NONSURGICAL TREATMENT, SEXUAL DYSFUNCTIONS, CLINICAL-EFFICACY, SINGLE-BLIND
- Akdeniz University Affiliated: Yes
Abstract
Introduction: Peyronie's disease (PD) is a wound-healing disorder of the penis and is estimated to affect 3 - 9% of men. Once believed to be a spontaneously resolving condition, it is now established that most cases of PD progress. The pathophysiology of PD involves the formation of collagenous plaques within the tunica albuginea with subsequent development of penile curvature or indentations of the penis. This may evolve into pain with erection and difficulty with intromission. PD follows a predictable natural history consisting of an acute phase characterized by progressive plaque formation with sometimes painful erections and a chronic phase in which plaques stabilize. Men with PD are hypothesized to have a genetic predisposition that causes abnormal wound healing, and some antecedent penile (micro) trauma, usually precipitated by sexual intercourse.